Curevac announces solid progress in phase 2 covid-19 and seasonal flu clinical development programs in collaboration with gsk

Covid-19 phase 2 clinical trial fully enrolled study compares mono- and bivalent vaccine candidates against licensed comparator covid-19 vaccine first participant dosed in seasonal flu phase 2 part of combined phase 1/2 study study compares a potentially differentiated, multivalent vaccine candidate with broad antigen coverage against licensed comparator vaccine tÜbingen, german and boston, ma / accesswire / november 1, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced solid progress in its clinical vaccine development programs in covid-19 and seasonal flu, conducted in collaboration with gsk.
CVAC Ratings Summary
CVAC Quant Ranking